OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Burtness on Combinations of Immunotherapy in Head and Neck Cancer

July 21st 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

July 21st 2017

Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

Dr. Cohen on CAR T-Cell Therapy for Head and Neck Cancer

July 20th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

July 19th 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

July 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

July 19th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma

July 19th 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma.

Dr. Stephenson on the Significance of a Study on Localized Prostate Cancer

July 19th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

Dr. Weiss Discusses Current Clinical Trials in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

July 19th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

Dr. Sankhala on Challenges Facing the Treatment of Angiosarcoma

July 19th 2017

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

July 19th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

July 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

July 18th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Dr. Hurria on Treatment Options for the Geriatric Population with Breast Cancer

July 17th 2017

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, discusses treatment for the geriatric patient population with breast cancer.

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

July 17th 2017

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

July 15th 2017

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Brufsky on the Disease-Free Survival of Aromatase Inhibitors for Breast Cancer

July 15th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

Dr. Hendifar on the Current Treatment Landscape in Pancreas Cancer

July 14th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the current treatment landscape in pancreas cancer.

Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

July 14th 2017

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.